Business, energy, technology, markets and global industry news from Business News Today

ADSTILADRIN

PharmaDeviceNews ADSTILADRIN
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More
Representative image of vial thawing in a clinical preparation setting, illustrating how Ferring Pharmaceuticals’ faster ADSTILADRIN thaw protocol could improve bladder cancer treatment workflow in BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground

FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.

Read More
Pharma & Biotech

Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation

ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.

Read More